Despite the announcement of the inclusion of the drug Zolgensma in the SUS (Unified Health System) in December 2022, the treatment remains unavailable to patients with Spinal Muscular Atrophy Type 1 and their families.

According to Novartis Brasil, manufacturer of the therapy, four meetings have been held with the Ministry of Health since the positive recommendation for incorporation, with the submission of two draft proposals.

Source: Folha de S.Paulo